Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons R.A. (Rudolf) de Boer

Publicaties

Associations of relative fat mass and BMI with all-cause mortality: Confounding effect of muscle mass

Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial

Deletion of DWORF does not affect cardiac function in ageing and in PLN-R14del cardiomyopathy

Early consequences of the phospholamban mutation PLN-R14del+/− in a transgenic mouse model

ECG-only Explainable Deep Learning Algorithm Predicts the Risk for Malignant Ventricular Arrhythmia in Phospholamban Cardiomyopathy

Mediators of the association between albuminuria and incident cancer: the PREVEND study

A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling

A Kinase Interacting Protein 1 regulates mitochondrial protein levels in energy metabolism and promotes mitochondrial turnover after exercise

Albuminuria and the risk of cancer: the Stockholm CREAtinine Measurements (SCREAM) project

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers

Lees meer

Pers/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'

Lees meer